Immunocore (NASDAQ:IMCR - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.
Several other research firms have also commented on IMCR. Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a report on Tuesday, May 27th. They set a "buy" rating and a $65.00 price target on the stock. Needham & Company LLC reiterated a "buy" rating and set a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. Oppenheimer lifted their price target on Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Immunocore in a report on Monday, June 2nd. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $58.89.
Read Our Latest Research Report on IMCR
Immunocore Price Performance
IMCR stock traded down $0.55 during midday trading on Friday, reaching $32.36. The stock had a trading volume of 438,334 shares, compared to its average volume of 362,333. The company's fifty day simple moving average is $31.35 and its 200 day simple moving average is $30.29. The company has a current ratio of 6.36, a quick ratio of 6.31 and a debt-to-equity ratio of 1.03. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -75.25 and a beta of 0.83. Immunocore has a 52-week low of $23.15 and a 52-week high of $41.54.
Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.45. Immunocore had a negative return on equity of 5.86% and a negative net margin of 6.48%. The business had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. During the same quarter in the previous year, the firm earned ($0.49) EPS. The company's quarterly revenue was up 33.6% compared to the same quarter last year. As a group, sell-side analysts predict that Immunocore will post -0.94 earnings per share for the current fiscal year.
Institutional Trading of Immunocore
A number of hedge funds and other institutional investors have recently modified their holdings of IMCR. Assetmark Inc. grew its position in Immunocore by 5.3% in the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company's stock valued at $949,000 after acquiring an additional 1,616 shares in the last quarter. Primecap Management Co. CA grew its position in Immunocore by 8.0% in the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock valued at $78,722,000 after acquiring an additional 196,530 shares in the last quarter. BIT Capital GmbH grew its position in Immunocore by 182.7% in the 4th quarter. BIT Capital GmbH now owns 67,840 shares of the company's stock valued at $2,001,000 after acquiring an additional 43,840 shares in the last quarter. NEOS Investment Management LLC grew its position in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after acquiring an additional 1,102 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Immunocore by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock valued at $1,047,000 after acquiring an additional 420 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.
About Immunocore
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Read More
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
